Impact of endothelial nitric oxide synthase activation on accelerated liver regeneration in a rat ALPPS model

Figure 6 Changes in liver regeneration and cell proliferation due to drug administration. A: Future liver remnant/body weight (FLR/BW) ratio in the N-nitro-arginine methyl ester (L-NAME)-administered associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) group; B: Ki-67 labeling index in the L-NAME-administered ALPPS group; C: FLR/BW ratio in the molsidomine-administered portal vein ligation (PVL) group; D: Ki-67 labeling index in the molsidomine-administered PVL group; n = 5 for each group; ^aP < 0.05; NS: Not significant; PVL: Portal vein ligation; ALPPS: Associating liver partition and portal vein ligation for staged hepatectomy; FLR/BW: Future liver remnant/body weight; L-NAME: N-nitro-arginine methyl ester.